Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986521 · 1 trial · 1 indication
Based on PET scans
| Arm | Type | Description |
|---|---|---|
| BMS-986521: Cohort 1 | EXPERIMENTAL | - |
| BMS-986521: Cohort 2 | EXPERIMENTAL | - |
| BMS-986521: Cohort 3 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986521 | DRUG | Specified dose on specified days |
Inclusion Criteria: * Participants must be healthy male and female (as assigned at birth) who are individuals not of childbearing potential (INOCBP) without clinically significant deviation from normal in medical history, PE, 12-lead ECG, and clinical laboratory assessments. * Participants must hav...
BMS-986521 is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development, with an ongoing positron emission tomography study assessing its occupancy of M4 muscarinic acetylcholine receptors in healthy adult participants.
BMS-986521 targets the M4 muscarinic acetylcholine receptor. A Phase 1 positron emission tomography study is evaluating the occupancy of these receptors by BMS-986521 in healthy adult participants, which helps determine how well the drug binds to its target in the brain.
BMS-986521 is being developed by Bristol-Myers Squibb Company, traded on the New York Stock Exchange under the ticker BMY. The company is conducting a Phase 1 clinical trial of this investigational small molecule in healthy volunteers.
BMS-986521 is in Phase 1 clinical development. It is an investigational drug, not yet approved, and is currently being studied in a recruiting Phase 1 trial in healthy volunteers. The trial is designed to assess receptor occupancy using positron emission tomography.
BMS-986521 is being studied in one active Phase 1 clinical trial, NCT07655518. This trial is a positron emission tomography study to assess the occupancy of M4 muscarinic acetylcholine receptors by BMS-986521 in healthy adult participants. The study is recruiting in Belgium with an enrollment of 12 participants.
No alternative names for BMS-986521 have been disclosed. The drug is identified solely by its compound code BMS-986521 in clinical trial records, and no other names or aliases are associated with it in the available information.